PPARγ Activation: A Potential Treatment for Pulmonary Hypertension

Science Translational Medicine

Volumn 1, Issue 12, 2009, Pages

  Hansmann, Georg ^a   Zamanian, Roham T ^b,c  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SIGNAL PEPTIDE;

ANIMAL; BLOOD PRESSURE; COOPERATION; DRUG EFFECT; DRUG POTENTIATION; GENETICS; HUMAN; INSULIN RESISTANCE; INTERDISCIPLINARY COMMUNICATION; METABOLISM; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; VASCULAR SMOOTH MUSCLE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; COOPERATIVE BEHAVIOR; HUMANS; HYPERTENSION, PULMONARY; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERDISCIPLINARY COMMUNICATION; MUSCLE, SMOOTH, VASCULAR; PPAR GAMMA; SIGNAL TRANSDUCTION; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME;

EID: 77954594805     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3000267     Document Type: Review

References (36)

1. P. M. Hassoun, L. Mouthon, J. A. Barberà, S. Eddahibi, S. C. Flores, F. Grimminger, P. L. Jones, M. L. Maitland, E. D. Michelakis, N. W. Morrell, J. H. Newman, M. Rabinovitch, R. Schermuly, K. R. Stenmark, N. F. Voelkel, J. X. Yuan, M. Humbert, Inflammation, growth factors, and pulmonary vascular remodeling. J. Am. Coll. Cardiol. 54 (suppl.), S10-S19 (2009).
2. N. W. Morrell, S. Adnot, S. L. Archer, J. Dupuis, P. L. Jones, M. R. MacLean, I. F. McMurtry, K. R. Stenmark, P. A. Thistlethwaite, N. Weissmann, J. X. Yuan, E. K. Weir, Cellular and molecular basis of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54 (suppl.), S20-S31 (2009).
3. R. D. Machado, O. Eickelberg, C. G. Elliott, M. W. Geraci, M. Hanaoka, J. E. Loyd, J. H. Newman, J. A. Phillips, 3rd, F. Soubrier, R. C. Trembath, W. K. Chung, Genetics and genomics of pulmonary arterial hypertension. J. Am. Coll. Cardiol. 54 (suppl.), S32-S42 (2009).
4. G. Hansmann, R. A. Wagner, S. Schellong, V. A. Perez, T. Urashima, L. Wang, A. Y. Sheikh, R. S. Suen, D. J. Stewart, M. Rabinovitch, Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 115, 1275-1284 (2007).
5. G. Hansmann, V. A. de Jesus Perez, T. P. Alastalo, C. M. Alvira, C. Guignabert, J. M. Bekker, S. Schellong, T. Urashima, L. Wang, N. W. Morrell, M. Rabinovitch, An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J. Clin. Invest. 118, 1846-1857 (2008).
6. R. T. Zamanian, G. Hansmann, S. Snook, D. Lilienfeld, K. M. Rappaport, G. M. Reaven, M. Rabinovitch, R. L. Doyle, Insulin resistance in pulmonary arterial hypertension. Eur. Respir. J. 33, 318-324 (2009).
7. G. Simonneau, I. M. Robbins, M. Beghetti, R. N. Channick, M. Delcroix, C. P. Denton, C. G. Elliott, S. P. Gaine, M. T. Gladwin, Z. C. Jing, M. J. Krowka, D. Langleben, N. Nakanishi, R. Souza, Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 54 (suppl.), S43-S54 (2009).
8. M. Oka, K. A. Fagan, P. L. Jones, I. F. McMurtry, Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br. J. Pharmacol. 155, 444-454 (2008).
9. S. Z. Duan, M. G. Usher, R. M. Mortensen, Peroxisome proliferator- activated receptor-gamma-mediated effects in the vasculature. Circ. Res. 102, 283-294 (2008).
10. T. Walcher, D. Walcher, J. Hetzel, C. Mielke, M. Rau, R. H. Böger, E. Schwedhelm, W. Koenig, N. Marx, Abstract 407: Rapid effect of single dose rosiglitazone treatment on endothelial function in healthy men with normal glucose tolerance: data from a randomized, placebo-controlled, double-blind study. Circulation 118, S-297 (2008). Available at http://circ.ahajournals.org/ cgi/content/meeting-abstract/118/18-MeetingAbstracts/S-297-e
11. M. W. Geraci, M. Moore, T. Gesell, M. E. Yeager, L. Alger, H. Golpon, B. Gao, J. E. Loyd, R. M. Tuder, N. F. Voelkel, Gene expression patterns in the lungs of patients with primary pulmonary hypertension: a gene microarray analysis. Circ. Res. 88, 555-562 (2001).
12. S. Ameshima, H. Golpon, C. D. Cool, D. Chan, R. W. Vandivier, S. J. Gardai, M. Wick, R. A. Nemenoff, M. W. Geraci, N. F. Voelkel, Peroxisome proliferator-activated receptor gamma (PPARgamma) expression is decreased in pulmonary hypertension and affects endothelial cell growth. Circ. Res. 92, 1162-1169 (2003).
13. S. Wakino, U. Kintscher, S. Kim, F. Yin, W. A. Hsueh, R. E. Law, Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1-> S transition in vascular smooth muscle cells. J. Biol. Chem. 275, 22435-22441 (2000).
14. D. Ogawa, T. Nomiyama, T. Nakamachi, E. B. Heywood, J. F. Stone, J. P. Berger, R. E. Law, D. Bruemmer, Activation of peroxisome proliferator-activated receptor gamma suppresses telomerase activity in vascular smooth muscle cells. Circ. Res. 98, e50-e59 (2006).
15. R. Summer, C. A. Fiack, Y. Ikeda, K. Sato, D. Dwyer, N. Ouchi, A. Fine, H. W. Farber, K. Walsh, Adiponectin deficiency: A model of pulmonary hypertension associated with pulmonary vascular disease. Am. J. Physiol. Lung Cell. Mol. Physiol. 297, L432-L438 (2009).
16. B. D. Medoff, Y. Okamoto, P. Leyton, M. Weng, B. P. Sandall, M. J. Raher, S. Kihara, K. D. Bloch, P. Libby, A. D. Luster, Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling. Am. J. Respir. Cell Mol. Biol. 41, 397-406 (2009).
17. P. Boucher, M. Gotthardt, W. P. Li, R. G. Anderson, J. Herz, LRP: Role in vascular wall integrity and protection from atherosclerosis. Science 300, 329-332 (2003).
18. Y. Wang, K. S. Lam, J. Y. Xu, G. Lu, L. Y. Xu, G. J. Cooper, A. Xu, Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. J. Biol. Chem. 280, 18341-18347 (2005).
19. J. Zhang, M. Fu, L. Zhao, Y. E. Chen, 15-Deoxy-prostaglandin J(2) inhibits PDGF-A and -B chain expression in human vascular endothelial cells independent of PPAR gamma. Biochem. Biophys. Res. Commun. 298, 128-132 (2002).
20. A. Gauthier, G. Vassiliou, F. Benoist, R. McPherson, Adipocyte low density lipoprotein receptor-related protein gene expression and function is regulated by peroxisome proliferator-activated receptor gamma. J. Biol. Chem. 278, 11945-11953 (2003).
21. C. Guignabert, C. M. Alvira, T. P. Alastalo, H. Sawada, G. Hansmann, M. Zhao, L. Wang, N. El-Bizri, M. Rabinovitch, Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta- dependent pulmonary arterial muscularization. Am. J. Physiol. Lung Cell. Mol. Physiol. 297, L1082-L1090 (2009).
22. H. Kato, H. Kashiwagi, M. Shiraga, S. Tadokoro, T. Kamae, H. Ujiie, S. Honda, S. Miyata, Y. Ijiri, J. Yamamoto, N. Maeda, T. Funahashi, Y. Kurata, I. Shimomura, Y. Tomiyama, Y. Kanakura, Adiponectin acts as an endogenous antithrombotic factor. Arterioscler. Thromb. Vasc. Biol. 26, 224-230 (2006).
23. R. E. Nisbet, J. M. Bland, D. J. Kleinhenz, P. O. Mitchell, E. R. Walp, R. L. Sutliff, C. M. Hart, Rosiglitazone attenuates chronic hypoxia-induced pulmonary hypertension in a mouse model. Am. J. Respir. Cell Mol. Biol. Published online 11 June 2009. http://www.ncbi.nlm.nih.gov/pubmed/19520921.
24. J. S. Yudkin, E. Eringa, C. D. Stehouwer, "Vasocrine" signalling from perivascular fat: a mechanism linking insulin resistance to vascular disease. Lancet 365, 1817-1820 (2005).
25. J. T. Kielstein, S. M. Bode-Böger, G. Hesse, J. Martens-Lobenhoffer, A. Takacs, D. Fliser, M. M. Hoeper, Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler. Thromb. Vasc. Biol. 25, 1414-1418 (2005).
26. G. P. Diller, S. van Eijl, D. O. Okonko, L. S. Howard, O. Ali, T. Thum, S. J. Wort, E. Bédard, J. S. Gibbs, J. Bauersachs, A. J. Hobbs, M. R. Wilkins, M. A. Gatzoulis, J. Wharton, Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation 117, 3020-3030 (2008).
27. S. Verma, M. A. Kuliszewski, S. H. Li, P. E. Szmitko, L. Zucco, C. H. Wang, M. V. Badiwala, D. A. Mickle, R. D. Weisel, P. W. Fedak, D. J. Stewart, M. J. Kutryk, C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109, 2058-2067 (2004).
28. X. X. Wang, F. R. Zhang, Y. P. Shang, J. H. Zhu, X. D. Xie, Q. M. Tao, J. H. Zhu, J. Z. Chen, Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J. Am. Coll. Cardiol. 49, 1566-1571 (2007).
29. Y. Takata, Y. Kitami, Z. H. Yang, M. Nakamura, T. Okura, K. Hiwada, Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma. Circ. Res. 91, 427-433 (2002).
30. C. S. Lee, Y. W. Kwon, H. M. Yang, S. H. Kim, T. Y. Kim, J. Hur, K. W. Park, H. J. Cho, H. J. Kang, Y. B. Park, H. S. Kim, New mechanism of rosiglitazone to reduce neointimal hyperplasia: activation of glycogen synthase kinase-3beta followed by inhibition of MMP-9. Arterioscler. Thromb. Vasc. Biol. 29, 472-479 (2009).
31. Y. Yu, S. H. Keller, C. V. Remillard, O. Safrina, A. Nicholson, S. L. Zhang, W. Jiang, N. Vangala, J. W. Landsberg, J. Y. Wang, P. A. Thistlethwaite, R. N. Channick, I. M. Robbins, J. E. Loyd, H. A. Ghofrani, F. Grimminger, R. T. Schermuly, M. D. Cahalan, L. J. Rubin, J. X. Yuan, A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation 119, 2313-2322 (2009).
32. K. N. Cowan, A. Heilbut, T. Humpl, C. Lam, S. Ito, M. Rabinovitch, Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat. Med. 6, 698-702 (2000).
33. S. Wakino, K. Hayashi, T. Kanda, S. Tatematsu, K. Homma, K. Yoshioka, I. Takamatsu, T. Saruta, Peroxisome proliferator-activated receptor gamma ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2. Circ. Res. 95, e45-e55 (2004).
34. J. T. Crossno, Jr, C. V. Garat, J. E. Reusch, K. G. Morris, E. C. Dempsey, I. F. McMurtry, K. R. Stenmark, D. J. Klemm, Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am. J. Physiol. Lung Cell. Mol. Physiol. 292, L885-L897 (2007).
35. See http://www.clinicaltrials.gov. Several RCTs currently investigate the therapeutic potential of pioglitazone in proliferative and inflammatory lung diseases, such as non-small-cell lung cancer (NCT00923949 and NCT00751725) and asthma (NCT00604578 and NCT00634036).
36. M. E. Risner, A. M. Saunders, J. F. Altman, G. C. Ormandy, S. Craft, I. M. Foley, M. E. Zvartau-Hind, D. A. Hosford, A. D. Roses; Rosiglitazone in Alzheimer's Disease Study Group, Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J. 6, 246-254 (2006).